Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Peintinger, F; Georgoulopoulos, A; Ralph, G; Piswanger, C.
Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age.
J Chemother. 2006; 18(6): 656-661.
Doi: 10.1179/joc.2006.18.6.656
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Peintinger Florentia
- Co-Autor*innen der Med Uni Graz
- Lipp-Solkner Claudia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We examined whether women aged 60 years or older with ovarian cancer who were treated with surgery and postoperative chemotherapy are at higher risk of developing grade 4 hematological toxicity. Seventy-five patients were included: 34 patients aged < 60 years (group I) were compared with 41 patients aged > or =60 years (group II) after postoperative treatment with single-agent carboplatin or carboplatin/taxane combination chemotherapy. Secondary prophylaxis with granulocyte colony-stimulating factors was performed to avoid dose reduction and chemotherapy delay. A total of 450 chemotherapy cycles was completed. Anemia and thrombocytopenia were mild in both groups. Overall, grade 4 neutropenia developed in 41% (group I) and in 49% (group II) (p=0.51). Febrile neutropenia occurred in 12% and 2%, respectively (p=0.17). The carboplatin/taxane combination was associated with grade 4 neutropenia in 42% (group I) and 58% (group II) (p=0.21). Women > or =60 years are not at higher risk of developing severe myelotoxicity than their younger counterparts, particularly after treatment with carboplatin/taxane combination chemotherapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Age Factors -
- Aged -
- Anemia - chemically induced
- Antineoplastic Agents - administration and dosage
- Carboplatin - adverse effects
- Drug Therapy, Combination - adverse effects
- Erythropoietin, Recombinant - therapeutic use
- Female - therapeutic use
- Granulocyte Colony-Stimulating Factor - therapeutic use
- Hematologic Diseases - chemically induced
- Humans - chemically induced
- Middle Aged - chemically induced
- Neutropenia - chemically induced
- Ovarian Neoplasms - drug therapy
- Postoperative Complications - drug therapy
- Retrospective Studies - drug therapy
- Risk Factors - drug therapy
- Taxoids - adverse effects
- Thrombocytopenia - chemically induced
- Find related publications in this database (Keywords)
- ovarian cancer
- myelotoxicity
- older patients